To evaluate the clinical and echocardiographic outcome of LCZ696 therapy in HFrEF (NYHA Class II - IV and EF =≤ 40%).patients, in addition to the efficacy of LCZ696 in reducing mortality and rehospitalisation rate.
Study Type
OBSERVATIONAL
Enrollment
100
LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
Cairo University
Cairo, Egypt
Number of Participants That Had Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization.
Number of participants that had either CV death or HF hospitalization due to HF.
Time frame: 6 Months after starting LCZ696 Therapy
Change From Baseline to Month 6 for The Minnesota Living with Heart Failure Questionnaire (MLHFQ).
Change From Baseline to Month 6 for the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The questionnaire was designed as a self-administered measure of the effects of heart failure and treatments for heart failure on patients' quality of life. The questionnaire has 21 items assess the impact of frequent physical symptoms of heart failure and the effects of heart failure on physical and social functions. The response scale for all 21 items on the MLHF is based on a 6-point ( from 0 to 5 ). Scores are transformed to a range of 0-105, in which higher scores reflect better health status.
Time frame: 6 Months after starting LCZ696 Therapy
Number of Patients - All-cause Mortality.
Number of patients - All-cause mortality. All-cause mortality is common in HF patients.
Time frame: 6 Months after starting LCZ696 Therapy
Number of Patients With First Confirmed Renal Dysfunction.
Number of patients with first confirmed renal dysfunction ( a decrease in the eGFR of at least 50% or a decrease of more than 30 ml per minute per 1.73 m2 to less than 60 ml per minute per 1.73 m2 ).
Time frame: 6 Months after starting LCZ696 Therapy
Number of Patients with Changes in The Left Ventricular Systolic Function (EF).
Number of Patients with improvement in the ejection fraction.
Time frame: 6 Months after starting LCZ696 Therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.